Navigation Links
Nuvelo Announces Presentation on NU206 at 2007 American Association,for Cancer Research Annual Meeting

SAN CARLOS, Calif., April 04, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that preclinical data evaluating the mechanism of action and role of NU206 (R-Spondin1) as a specific and potent stimulator of the gastrointestinal (GI) epithelial cells will be presented in an educational session at the 2007 American Association for Cancer Research (AACR) Annual Meeting taking place at the Los Angeles Convention Center in Los Angeles, CA, April 14-18, 2007.

    The presentation details are as follows:

          Date/Time: Saturday, April 14, 2007, 8:00-10:00 a.m. PDT

          Location: Room 403 A-B, Los Angeles Convention Center

          Session/Abstract Title: Therapeutic Cancer Targets in the Wnt

          Pathway/R-Spondin, novel regulators of the Wnt/b-catenin signaling


    About NU206

NU206, also known as human R-spondin1, is a recombinant, secreted protein that has the potential to act as a potent and highly specific growth factor of GI epithelial cells. In early animal model studies, NU206 promoted growth and repair of these tissues in models of radiation treatment or chemotherapy, as well as in animal models of inflammatory bowel disease and short bowel syndrome. A publication in the August 2005 issue of Science described results from studies in animal models of mucositis, where NU206 was shown to diminish symptoms of mucositis, including diarrhea and weight loss.

About Nuvelo and Kirin's Joint Collaborative Effort

Scientists from Nuvelo and Kirin worked together to identify and characterize NU206 as part of a collaboration focused on the discovery of novel, secreted proteins. NU206 is the first compound to enter preclinical studies from this program. Nuvelo signed a collaboration agreement with Kirin in April 2005 to develop NU206. Under the agreement, Nuvelo leads worldwide development, manufacturing and commercialization and all operating expenses and p
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... , Weltweite Exklusivlizenz ... ermöglicht QIAGEN die Entwicklung von Tests auf ... Blutkrebs  Neuer Test weist Mutationen ... Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten ...
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
(Date:7/24/2014)... VANCOUVER, British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today ... the company,s fiscal year from December 31 to June 30. ... before September 30, 2014. Jeffrey Bacha , ... year end is an important step in achieving our goal ...
Breaking Medicine Technology:QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3
... SAN DIEGO, May 26, 2011 Volcano Corporation ... following statement: Earlier this year, the ... a wholly-owned subsidiary of St. Jude Medical, that ... misappropriated LightLab,s confidential information in connection for use ...
... YORK, May 26, 2011 A new prostate cancer ... Medicine comparing surgical treatment to "watchful waiting" ... cancer and currently debating their treatment options. ... the most commonly offered clinical options for early prostate ...
Cached Medicine Technology:Statement From Volcano Corporation on Latest St. Jude Lawsuit 2Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 2Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment 3
(Date:7/25/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... Heather M. Young, PhD, RN, FAAN, of the ... of the Doris Schwartz Gerontological Nursing Research Award. ... Sciences Section, is given to a member of ... contribution to gerontological nursing research. , The award ...
(Date:7/25/2014)... by People Magazine in the article Mike 'The Situation' ... (7/15), one of the most popular cast stars from MTV's ... about his personal transformation. Now, two years later since the ... with his life was a challenge. He was previously addicted ... even spent some time in rehab. He took the opportunity ...
(Date:7/25/2014)... Merrill Corporation ( http://www.merrillcorp.com ), ... the financial, legal, healthcare and other corporate markets, ... Merrill DataSite, has been recognized as the “Technology ... the M&A Awards 2014 event. , ... management teams, advisors and financiers as they demonstrate ...
(Date:7/25/2014)... 2014 Ticket Down is a ... tickets in Berkeley at California Memorial Stadium. With the ... of football, the organizers of the 2014 Guinness International Champions ... to North America. With teams representing La Liga, English Premier ... some of the best football players from around the world ...
(Date:7/25/2014)... July 25, 2014(BRONX, NY)A study involving nearly 27,000 older ... 10 met criteria for pre-dementia based on a simple ... they have cognitive complaints. People who tested positive for ... dementia within 12 years. The study, led by scientists ... Yeshiva University and Montefiore Medical Center , was ...
Breaking Medicine News(10 mins):Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Merrill DataSite Recognized as “Technology Provider of the Year” by GrowthBusiness at the M&A Awards 2014 Event 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4
... us are counting,down the days leading up to the ... Council of America reminds you that time is running ... your flexible spending,account., Made available through employers, flexible ... pay for out-of-pocket health expenses,such as an eye exam ...
... CEO, Will Continue Serving as Chairman of the Board, ... Bulletin Board: MLSS), the recognized leader in,advanced injection technologies, ... Martin, Chief Executive Officer of the Company,s,medical division, as ... of its Board,of Directors, effective January 1, 2008. As ...
... A study led by Massachusetts General Hospital (MGH) researchers ... fibrosis (IPF), a usually fatal lung disease for which ... that a specific molecular pathway appears responsible for key ... IPF, the cause of which is currently unknown. ...
... has been shown to improve the sleep quality and ... most commonly-used medication, according to research published today in ... the effects of the new drug dexmedetomidine with the ... pain and anxiety experienced by mechanically ventilated ICU patients ...
... Philadelphia, PA, December 12, 2007 Major depressive disorder ... almost one in five individuals. More than 75% of ... have at least one recurrence, with the majority having ... disability of all medical illnesses, with substantial functional impairment, ...
... the fight against cancer: Recent research at the University ... Ganoderma lucidum aid in suppressing some of the mechanisms ... action of the fungus: disrupting androgen receptor activity and ... the past 3-4 decades much scientific research has dealt ...
Cached Medicine News:Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 2Health News:Joe Martin Appointed CEO of Milestone Scientific and New Executive Member of the Board of Directors 3Health News:Molecular pathway appears crucial in development of pulmonary fibrosis 2Health News:Intensive care quality of sleep improved by new drug, reports study 2Health News:Venlafaxine extended-release effective for patients with major depression 2Health News:Active compounds found in Ganoderma lucidum fungus with potential to treat prostate cancer 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: